)
)
Therapeutic Antibody Discovery From Disease-Resilient Individuals Through Bulk and Single Cell Immune Repertoire Sequencing
-
Alchemab identifies resilient individuals with expected susceptibility to a particular disease but who show limited or no progression
-
We perform deep sequencing of their B cell receptor sequences to find protective antibodies, then determine their targets and investigate mechanisms of action
-
Presentation will highlight a case study of a therapeutic antibody discovered from patients resilient to neurodegenerative disease that is progressing towards the clinic
